LKFT Lakefront Biotherapeutics - American Depositary Shares
Lakefront Biotherapeutics - American Depositary Shares 정보 위키백과 회사 개요
Lakefront Biotherapeutics is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.
더 보기
Lakefront Biotherapeutics (formerly known as Galapagos NV and Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.
The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis.
History
Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell and Tibotec. The company later changed its name to Galapagos NV and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005.
The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.
In 2019, Gilead Sciences and Galapagos entered into transformative research and development collaboration. Gilead and Galapagos have also agreed to amend certain terms around the development and commercialization of filgotinib.
In June 2022, the business announced it would acquire CellPoint for €125 million, with milestones of up to €100 million and AboundBio for $14million.
Effective April 1, 2022 Paul Stoffels replaced cofounder and CEO of 20 years Onno van de Stolpe.
In April 2026 the company was renamed to Lakefront Biotherapeutics.
Company
A German company, Galapagos Biopharma Germany GmbH, was established in 2019 and is headquartered in Munich, Germany. In December 2021, the company established an Austrian subsidiary, Galapagos Biopharma Austria GmbH, headquartered in Vienna, Austria.
Drugs
Filgotinib (GLPG0634) a selective inhibitor of JAK1 (Janus kinase 1) being developed for the treatment of rheumatoid arthritis and potentially Crohn's disease.
GLPG1205: a first-in-class GPR84-inhibitor currently under research for the treatment of inflammatory bowel disease.
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
이 티커에 대한 기본 데이터가 아직 없습니다.
행동주의자 및 5% 이상 소유자 3 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC, Oleg Nodelman, EcoR1 Capital Fund Qualified, L.P., EcoR1 Capital Fund, L.P. ×4 제출 서류 | 2025년 7월 28일 | 13.22% | 수정본 | — | SEC |
| TANG CAPITAL MANAGEMENT, LLC, KEVIN TANG, TANG CAPITAL PARTNERS, LP, TANG CAPITAL PARTNERS INTERNATIONAL, LP, TANG CAPITAL PARTNERS III, INC, TANG CAPITAL PARTNERS IV, INC, CONCENTRA BIOSCIENCES, LLC | 2025년 2월 14일 | 7.50% | 최초 제출 | — | SEC |
| Van Herk Investments B.V., Van Herk Investments THI B.V., Van Herk Private Equity Investments B.V., Stichting Administratiekantoor Penulata, Van Herk Management Services B.V., Onroerend Goed Beheer – en Beleggingsmaatschappij A. van Herk B.V., A. van Herk Holding B.V., Stichting Administratiekantoor Abchrys, Adrianus van Herk | 2021년 11월 2일 | — | 최초 제출 | 이사회 캠페인 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF 보유 현황 18 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| EWK · iShares, Inc. | 0.58% | 37,133 SH | 2026년 8월 8일 | 일간 |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.47% | 3,949 SH | 2026년 8월 8일 | 일간 |
| IBB · iShares Trust | 0.08% | 305,498 SH | 2026년 8월 8일 | 일간 |
| PDN · Invesco Exchange-Traded Fund Trust … | 0.07% | 9,655 SH | 2026년 8월 8일 | 일간 |
| IEUS · iShares Trust | 0.05% | 3,396 SH | 2026년 8월 8일 | 일간 |
| VSS · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.04% | 188,173 SH | 2026년 8월 8일 | 일간 |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.03% | 815 SH | 2026년 8월 8일 | 일간 |
| SCZ · iShares Trust | 0.02% | 113,209 SH | 2026년 8월 8일 | 일간 |
| VGK · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.01% | 119,870 SH | 2026년 8월 8일 | 일간 |
| WSML · iShares Trust | 0.01% | 2,543 SH | 2026년 8월 8일 | 일간 |
| IEUR · iShares Trust | 0.01% | 27,247 SH | 2026년 8월 8일 | 일간 |
| IEFA · iShares Trust | 0.00% | 320,356 SH | 2026년 8월 8일 | 일간 |
| IDEV · iShares Trust | 0.00% | 40,908 SH | 2026년 8월 8일 | 일간 |
| IXUS · iShares Trust | 0.00% | 62,087 SH | 2026년 8월 8일 | 일간 |
| VXUS · VANGUARD STAR FUNDS | 0.00% | 717,158 SH | 2026년 8월 8일 | 일간 |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.00% | 36,160 SH | 2026년 8월 8일 | 일간 |
| VEA · VANGUARD TAX-MANAGED FUNDS | 0.00% | 483,750 SH | 2026년 8월 8일 | 일간 |
| VSGX · VANGUARD WORLD FUND | 0.00% | 9,595 SH | 2026년 8월 8일 | 일간 |